Setting watch price at $300 to re-evaluate. Meanwhile…
ISRG closed Friday (7/17) at $345.42, down 14% that day and roughly 30% off its highs, after Q2 2026 earnings beat but management flagged slower US procedure growth. No news over the weekend, so Monday’s open should be close to that level.
What happened Thursday night: Revenue came in at $2.89B (+19% YoY), non-GAAP EPS $2.80 (+28% YoY), and total procedures grew 16%, driven by 15% da Vinci growth and 36% growth in Ion (their smaller bronchoscopy platform). The company actually raised gross margin guidance to 68-69% from 67.5-68.5%, and da Vinci 5 placements jumped 37%. The stock sold off anyway because US da Vinci procedure growth moderated to 12%, tied to shifts in patient insurance coverage and premium dynamics, and full-year procedure growth guidance (13.5-15.5%) was left unchanged rather than raised despite the beat. Investors read that as the growth story decelerating, not the numbers themselves.
Valuation: Forward P/E is around 33x versus a medical device industry median near 19x, so it’s still priced at a real premium even after a 30% haircut. Historically ISRG has traded 40-50x forward earnings, so this is cheap relative to its own history but not cheap in absolute terms. Analysts cut price targets across the board after the print (Evercore $430→$375, Citi $590→$500, Bernstein $750→$685), but the consensus 12-month target still sits around $505-520, roughly 45-50% above Friday’s close, and the rating consensus is Buy.
Moat: This is the strongest part of the case. Installed base is 11,395 systems (+12% YoY), da Vinci 5 took 85% of US placements in Q1, and 85% of revenue is recurring (instruments, service, accessories) rather than one-time system sales. Surgeon training and hospital capital commitments create real switching costs. Medtronic’s Hugo and J&J’s Ottava are trying to break in but haven’t dented ISRG’s US share yet.
Risks: slowing US procedure growth is the thing that just moved the stock and could keep pressuring the multiple if it doesn’t stabilize; tariffs are a live cost overhang; and a 33x multiple leaves little room for another disappointing quarter. Competitive entry from Medtronic and J&J is a multi-year risk, not an immediate one, but it’s the reason the premium won’t expand back to 45x+ anytime soon.
⭐ I’d treat this as a name worth starting a position in now rather than waiting, sized small, with room to add if it drifts lower on continued guidance jitters. The selloff was about decelerating growth, not a broken thesis, and the moat/recurring-revenue mix is intact. But I wouldn’t back up the truck at 33x on a first tranche.
❌ Wait for the next print to confirm growth stabilizes: reasonable if you want confirmation, but you’re betting the stock doesn’t re-rate back toward $400+ in the meantime, which is plausible given the Buy-rated analyst base. ❌ Skip it as too expensive even post-drop: defensible on pure multiple grounds, but ignores that ISRG has rarely traded this cheap relative to its own history and the moat is arguably getting stronger, not weaker.
I’m not a financial advisor and this isn’t a personalized recommendation, just how I read the setup. Worth noting you don’t currently hold ISRG anywhere in the accounts I can see, and it’d be a straight growth/health-tech add with no dividend, which fits differently depending on which account you’re funding it from.
Sources:
- Intuitive Surgical (ISRG) Down 30% This Year; Can Tonight’s Q2 Earnings Reverse the Bearish Channel?
- Intuitive Surgical Q2 Earnings Call Highlights
- How Q2 Earnings Beat, Buybacks and Softer Guidance At Intuitive Surgical (ISRG) Has Changed Its Investment Story – Simply Wall St
- INTUITIVE SURGICAL Forward PE Ratio – GuruFocus
- ISRG Maintained by Bernstein — Price Target Lowered to $685
- ISRG Maintains by Evercore ISI Group — Price Target Lowered to $375
- Intuitive Surgical’s Moat Is Getting Stronger – The Motley Fool
- How ISRG Just Secured The U.S. Market – Trefis